| P2093 | author name string | Zemin Yao | |
| | Zhenghui Gordon Jiang | |
| | Simon C Robson | |
| P2860 | cites work | Alcoholic Fatty Liver | Q39977693 |
| | Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts | Q39984968 |
| | Apolipoprotein A-V association with intracellular lipid droplets | Q40140841 |
| | Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease | Q40163524 |
| | Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes | Q40416571 |
| | Lipoprotein and receptor interactions in vivo. | Q40540753 |
| | The lipid binding activity of the exchangeable apolipoprotein apolipophorin-III correlates with the formation of a partially folded conformation | Q42060303 |
| | Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis | Q42644245 |
| | High plasma immunoglobulin (Ig) A and low IgG antibody titers to oxidized low-density lipoprotein are associated with markers of glucose metabolism | Q43120687 |
| | Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. | Q43494872 |
| | Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia | Q43826571 |
| | Hypobetalipoproteinemic mice with a targeted apolipoprotein (Apo) B-27.6-specifying mutation: in vivo evidence for an important role of amino acids 1254-1744 of ApoB in lipid transport and metabolism of the apoB-containing lipoprotein | Q43882521 |
| | Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease | Q43887102 |
| | Apolipoprotein synthesis in nonalcoholic steatohepatitis | Q43933950 |
| | Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States | Q44269254 |
| | Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity | Q44766939 |
| | Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. | Q44902058 |
| | The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk | Q45171313 |
| | The enhanced association of apolipoprotein E with apolipoprotein B-containing lipoproteins in serum-stimulated hepatocytes occurs intracellularly | Q46151264 |
| | Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. | Q46242854 |
| | Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia | Q46345830 |
| | Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis | Q46605919 |
| | Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis | Q46792613 |
| | Overproduction of large VLDL particles is driven by increased liver fat content in man. | Q46931621 |
| | Abetalipoproteinemia: two case reports and literature review | Q21202911 |
| | An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing | Q24291759 |
| | Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia | Q24294711 |
| | The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins | Q24311849 |
| | An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms | Q24562942 |
| | Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease | Q24611284 |
| | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 |
| | Structure and dynamics of human apolipoprotein CIII | Q27650312 |
| | Crystal Structure of C-terminal Truncated Apolipoprotein A-I Reveals the Assembly of High Density Lipoprotein (HDL) by Dimerization | Q27673796 |
| | The Structure of Dimeric Apolipoprotein A-IV and Its Mechanism of Self-Association | Q27679028 |
| | Familial hypobetalipoproteinemia: a review | Q28183795 |
| | Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice | Q28215647 |
| | Familial hypobetalipoproteinemia: genetics and metabolism | Q28244204 |
| | Clinical review#: Lipodystrophies: genetic and acquired body fat disorders | Q28246346 |
| | Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions | Q28252652 |
| | Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia | Q28271254 |
| | Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha | Q28273937 |
| | Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies | Q28281855 |
| | Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease | Q28282463 |
| | Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia | Q28282776 |
| | Apolipoprotein E: cholesterol transport protein with expanding role in cell biology | Q28294791 |
| | Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion | Q38003911 |
| | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates | Q38316076 |
| | A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia | Q38358309 |
| | Apolipoprotein E polymorphism in health and disease | Q39756689 |
| | The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins | Q47732277 |
| | Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon | Q48336804 |
| | Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. | Q50715903 |
| | Structural properties of the microsomal triglyceride-transfer protein complex. | Q50803798 |
| | Liver lipids of female Carcharias taurus (spotted raggedtooth) sharks: a comparison between seasons. | Q51156588 |
| | Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study | Q51541188 |
| | Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. | Q55033443 |
| | Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease | Q58622754 |
| | The role of apolipoprotein A5 in non-alcoholic fatty liver disease | Q61451349 |
| | Hepatic peroxisomal abnormalities in abetalipoproteinemia | Q69665655 |
| | Acute fatty liver of pregnancy | Q69897420 |
| | Mechanism of microsomal triglyceride transfer protein catalyzed lipid transport | Q70480635 |
| | Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus | Q70541255 |
| | Type III hyperlipoproteinemia associated with apolipoprotein E deficiency | Q71576154 |
| | Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression | Q72018329 |
| | Binding of microsomal triglyceride transfer protein to lipids results in increased affinity for apolipoprotein B: evidence for stable microsomal MTP-lipid complexes | Q74101733 |
| | Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes | Q74319412 |
| | Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia | Q77840441 |
| | Insulin dose response analysis of free fatty acid kinetics | Q79425605 |
| | Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? | Q80229572 |
| | Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia | Q80520286 |
| | Microsomal triglyceride transfer protein 493-T variant is associated with resistin levels and C-reactive protein | Q81159257 |
| | The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation | Q81350918 |
| | APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia | Q81944118 |
| | Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis | Q83334976 |
| | Apolipoprotein CIII: 42 years old and even more interesting | Q83421494 |
| | A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease | Q83476095 |
| | Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease | Q83862815 |
| | Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease | Q83897747 |
| | Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice | Q84526280 |
| | LXRS and FXR: the yin and yang of cholesterol and fat metabolism | Q28295718 |
| | A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine | Q28301876 |
| | Complete protein sequence and identification of structural domains of human apolipoprotein B | Q28304536 |
| | Molecular diagnosis of hypobetalipoproteinemia: an ENID review | Q28306392 |
| | A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides | Q28507306 |
| | Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia | Q28565000 |
| | ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes | Q28569109 |
| | Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E | Q28577984 |
| | Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly | Q28624200 |
| | Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity | Q29614932 |
| | The natural history of nonalcoholic fatty liver disease: a population-based cohort study | Q29617161 |
| | Weight-reducing effects of the plasma protein encoded by the obese gene | Q29617934 |
| | Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 |
| | Nonalcoholic fatty liver disease | Q29619354 |
| | Epidemiology of non-alcoholic fatty liver disease in China. | Q30373353 |
| | Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond | Q33702396 |
| | A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion | Q33741229 |
| | Molecular basis of exchangeable apolipoprotein function | Q33796767 |
| | Non-alcoholic fatty liver disease: what's new under the microscope? | Q33815033 |
| | The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. | Q33881217 |
| | Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia | Q33987896 |
| | Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia | Q33988456 |
| | Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease | Q33990346 |
| | The Role of PPARα Activation in Liver and Muscle | Q34106233 |
| | Cholesterol and mortality. 30 years of follow-up from the Framingham study | Q34183820 |
| | Regulation of plasma cholesterol by lipoprotein receptors | Q34252363 |
| | PPAR gamma and human metabolic disease | Q34416432 |
| | Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. | Q34459818 |
| | Apolipoprotein E: From lipid transport to neurobiology | Q34497951 |
| | Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo | Q34546130 |
| | A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 |
| | Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins | Q34634838 |
| | Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance | Q34674263 |
| | Adipose tissue as a buffer for daily lipid flux | Q34872471 |
| | Lipoprotein lipase: from gene to obesity | Q34968373 |
| | ??? | Q28240856 |
| | Liver X Receptor Signaling Pathways in Cardiovascular Disease | Q35104848 |
| | Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. | Q35186665 |
| | Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy | Q35210714 |
| | Leptin in human physiology and pathophysiology. | Q35321788 |
| | Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance | Q35489364 |
| | High-density lipoprotein heterogeneity and function in reverse cholesterol transport | Q35546972 |
| | Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis | Q35597601 |
| | Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia | Q35767718 |
| | Lipid disorders and mutations in the APOB gene. | Q35861929 |
| | New wrinkles in lipoprotein lipase biology. | Q36060371 |
| | Regulation of plasma triglycerides in insulin resistance and diabetes | Q36144459 |
| | Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents | Q36183590 |
| | FXR, a multipurpose nuclear receptor | Q36565306 |
| | MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? | Q36709542 |
| | Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets | Q36721566 |
| | Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus | Q36738703 |
| | Reconstituting initial events during the assembly of apolipoprotein B-containing lipoproteins in a cell-free system. | Q37087690 |
| | FoxO1 integrates insulin signaling to VLDL production | Q37148966 |
| | Intestinal lipoprotein overproduction in insulin-resistant states | Q37156290 |
| | Ethnic differences in hepatic steatosis: an insulin resistance paradox? | Q37175282 |
| | Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. | Q37250895 |
| | Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. | Q37310292 |
| | Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis | Q37318430 |
| | Circulatory lipid transport: lipoprotein assembly and function from an evolutionary perspective | Q37364539 |
| | Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes | Q37375894 |
| | Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance | Q37552186 |
| | Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. | Q37597603 |
| | Peroxisome proliferator-activated receptor translational research and clinical experience | Q37634781 |
| | Rationale for leptin-replacement therapy for severe lipodystrophy. | Q37671402 |
| | Apolipoprotein B synthesis inhibition: results from clinical trials | Q37761290 |
| | A role of the bile salt receptor FXR in atherosclerosis | Q37772712 |
| | Triglyceride lipases and atherosclerosis | Q37777604 |
| | Liver transplantation using fatty livers: always feasible? | Q37818981 |
| | Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground | Q37825661 |
| P433 | issue | 1 | |
| P921 | main subject | liver disease | Q929737 |
| | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| | fatty liver disease | Q6058862 |
| | lipoprotein | Q28350 |
| P304 | page(s) | 1-13 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Journal of biomedical research | Q26842836 |
| P1476 | title | Lipoprotein metabolism in nonalcoholic fatty liver disease | |
| P478 | volume | 27 | |